Calprotectin Test Kit Growth, Trends & Forecast Outlook 2033

Calprotectin Test Kit by Application (In Vitro Diagnostics, Scientific Research), by Types (ELISA, Immuno Turbidimetric, Lateral Flow, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 198

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 198

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Calprotectin Test Kit Market Size | CAGR 7.5 Forecast 2033

Calprotectin Test Kit Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 198

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 198

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Calprotectin Test Kit Market Overview

The Calprotectin Test Kit market comprises in‑vitro diagnostic kits that quantitatively measure fecal calprotectin to aid in the detection and management of inflammatory bowel disease (IBD). Its clinical relevance lies in offering a non‑invasive, rapid screening tool that reduces reliance on endoscopy. The Calprotectin Test Kit market size was estimated at USD 680 million in 2025, and analysts project a CAGR of 9.2% through the 2026‑2033 market forecast, signaling robust industry expansion driven by rising IBD prevalence, aging populations, and heightened awareness of early diagnostics. The market scope covers ELISA, lateral flow, and automated immunoassay formats across hospital laboratories, point‑of‑care clinics, and research institutions.

Loading chart…

Key forces shaping the market include technological innovation—notably the shift toward point‑of‑care lateral flow platforms that shorten turnaround time, regulatory alignment with stricter IBD screening guidelines in major economies, and supply‑chain resilience as manufacturers diversify raw‑material sourcing. Europe remains the largest region, anchored by mature healthcare systems and reimbursement frameworks, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding middle‑class access, increasing gastro‑enterology services, and government‑backed screening initiatives. These dynamics collectively underpin a compelling growth narrative for stakeholders across the value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Actim; Svar Life Science(Calpro); BÜHLMANN Laboratories; EagleBio; CerTest Biotec; Euroimmun; Boditech Med; Biohit; ALPCO Diagnostics; DiaSource Diagnostics; R-Biopharm; Abbexa; AccuBio Tech; Screen Italia; Biotests; Thermo Fisher Scientific; Epitope Diagnostics; Elabscience Biotechnology; Vitassay Healthcare; AVA Technology; DiaSorin; BioVendor; Xiamen Weizheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The escalating prevalence of inflammatory bowel disease (IBD) across North America and Europe, and an aging population, is fueling demand for non‑invasive diagnostics, directly expanding the Calprotectin Test Kit market size and underpinning a double‑digit growth forecast through 2032.

Rapid adoption of automated ELISA and point‑of‑care platforms shortens turnaround time to under 30 minutes, enabling outpatient clinics to replace colonoscopy‑based screening, which accelerates revenue streams, reduces labor costs for lab technicians, and reinforces the upward trajectory of the Calprotectin Test Kit market.

Restraints2 items

High per‑test pricing, driven by proprietary antibodies and quality‑control requirements, limits adoption in cost‑sensitive public hospitals, constrains the Calprotectin Test Kit market’s penetration in emerging economies, and limited reimbursement frameworks temper the overall growth forecast.

Regulatory heterogeneity—particularly divergent CE‑Mark and FDA pathways—extends time‑to‑market for new kits, imposing additional validation costs that deter smaller manufacturers, raise entry barriers for innovators, and compress the Calprotectin Test Kit market size expansion.

Opportunities2 items

Integration of Calprotectin assays with tele‑health platforms and AI‑driven result interpretation creates bundled service offerings, unlocking recurring revenue models, improving patient adherence, and positioning the market for a sustained growth forecast beyond 2028.

Strategic partnerships with gastroenterology networks in Asia‑Pacific are opening high‑volume testing channels, where rising IBD awareness and expanding private‑clinic infrastructure can markedly boost the Calprotectin Test Kit market size, projected to grow at a CAGR of 9%.

Challenges2 items

Global shortages of high‑purity monoclonal antibodies, exacerbated by pandemic‑induced raw‑material constraints, threaten kit production schedules, forcing manufacturers to hedge inventories, may delay new product launches, and potentially erode profit margins.

Intensifying competition from multiplex gastrointestinal panels drives price wars, compelling vendors to differentiate through value‑added services rather than core assay cost, adding complexity to commercial strategies and necessitating robust pricing analytics.

Market Segmentation

Loading chart…

The application segment of the Calprotectin Test Kit market is divided into three primary uses: IBD diagnosis, disease monitoring, and research. IBD diagnosis accounts for the largest share, reflecting the test's established role in differentiating inflammatory bowel disease from functional disorders such as irritable bowel syndrome. This application drives the bulk of kit sales because it is routinely ordered in primary‑care and gastroenterology settings, contributing roughly 55 % of total market revenue. Disease monitoring represents a growing niche, where clinicians employ serial calprotectin measurements to assess treatment response and predict relapse, currently generating about 30 % of market value. The research category, though smaller at 15 %, supports academic and pharmaceutical investigations into gut inflammation pathways and new therapeutic targets, ensuring a steady demand for specialized kits. Together, these applications define the overall market size, and the distribution of revenue across them is captured in the Calprotectin Test Kit segmentation analysis.

The types segment classifies Calprotectin Test Kits by analytical format, encompassing ELISA‑based kits, lateral‑flow immunoassays, point‑of‑care (POC) devices, and automated immunoassay platforms. ELISA‑based kits dominate the market due to their high sensitivity, quantitative output, and compatibility with existing laboratory infrastructure, typically representing the majority of sales. Lateral‑flow immunoassays, favored for rapid bedside testing, capture a modest but expanding share as healthcare providers seek faster turnaround times. Point‑of‑care devices, integrating cartridge‑based chemistry with handheld readers, are gaining traction in outpatient and remote settings, driven by the need for immediate clinical decisions. Automated immunoassay platforms, employed by high‑volume central labs, offer high throughput and reduced hands‑on time, contributing a distinct revenue stream. Each type addresses specific workflow requirements, and their combined adoption shapes the total market volume, reinforcing the comprehensive Calprotectin Test Kit segmentation framework.

Calprotectin Test Kit Segmentation Breakdown8 items

Application

In Vitro Diagnostics

Scientific Research

Types

ELISA

Immuno Turbidimetric

Lateral Flow

Other

Regional Insights

Loading chart…

The Calprotectin Test Kit market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic reimbursement frameworks, expanding gastro‑intestinal disease awareness, and robust diagnostic infrastructure drive distinct momentum across geographies.

North America benefits from mature healthcare ecosystems, aggressive payer reimbursement policies, and sustained private‑sector investment in point‑of‑care diagnostics. High prevalence of inflammatory bowel disease (IBD) and the adoption of digital health platforms further accelerate test‑kit utilization.

Europe’s market is propelled by comprehensive national screening programs, especially in Germany and the UK, and strong public‑private partnerships that fund laboratory modernization. Regulatory harmonization under the EU IVDR also streamlines product entry, while aging demographics increase demand for chronic disease monitoring.

Asia Pacific’s rapid expansion stems from rising middle‑class income, escalating IBD incidence, and government initiatives promoting early diagnosis in China, India, and Japan. Investments in hospital networks and a surge in outsourced laboratory services create a fertile environment for test‑kit adoption.

Latin America sees incremental growth driven by expanding private healthcare coverage, especially in Brazil and Mexico, and increasing awareness campaigns led by gastroenterology societies. However, infrastructure constraints temper the pace of market penetration.

Middle East & Africa exhibit nascent but promising activity, fueled by UAE and Saudi Arabia’s health‑sector diversification plans and rising diagnostic capacity. Partnerships with multinational OEMs and targeted training programs are key to unlocking future demand.

Competitive Landscape

The Calprotectin Test Kit competitive landscape is moderately consolidated, with a handful of multinational manufacturers coexisting alongside a growing cohort of regional suppliers. Global players leverage extensive distribution networks and regulatory certifications to command price premiums, while local firms compete on cost efficiency and rapid market entry. Pricing elasticity, breadth of product portfolios, and attainment of CE‑IVD or FDA clearance serve as primary differentiators. Distribution agreements with hospital groups and laboratory service providers further shape market dynamics. Regulatory pathways differ across regions, prompting manufacturers to maintain parallel dossiers for CE‑IVD, FDA, and Asian clearances. Channel strength is reinforced by collaborations with reagent distributors and point‑of‑care OEMs, expanding reach into community labs.

Companies pursue a mix of inorganic and organic tactics to protect or expand market share. Recent years have seen multiple M&A transactions aimed at acquiring complementary assay platforms, while strategic partnerships with diagnostic service networks accelerate geographic rollout. Product launches focus on multiplex panels and automated formats that promise reduced hands‑on time. Firms also invest in localized manufacturing to mitigate supply‑chain volatility and to satisfy country‑specific regulatory demands. Digital integration, like cloud‑based reporting, differentiates vendors targeting large hospital networks. Bundled service contracts for calibration, maintenance, and training lock in recurring revenue. Assay formats are edging toward commoditization, pressuring firms to justify price gaps with value‑added services.

Actim – regional expansion in Eastern Europe

Svar Life Science (Calpro) – OEM tie‑ups for hospital systems

BÜHLMANN Laboratories – premium pricing for automated platforms

EagleBio – local manufacturing to reduce supply‑chain risk

CerTest Biotec – innovation pipeline targeting multiplex assays

Euroimmun – vertical integration of reagent and diagnostic services

Key Calprotectin Test Kit Companies23 items

Actim

Svar Life Science(Calpro)

BÜHLMANN Laboratories

EagleBio

CerTest Biotec

Euroimmun

Boditech Med

Biohit

ALPCO Diagnostics

DiaSource Diagnostics

R-Biopharm

Abbexa

AccuBio Tech

Screen Italia

Biotests

Thermo Fisher Scientific

Epitope Diagnostics

Elabscience Biotechnology

Vitassay Healthcare

AVA Technology

DiaSorin

BioVendor

Xiamen Weizheng Biotechnology

Market Ecosystem

The Calprotectin Test Kit ecosystem spans from raw material sourcing through kit assembly to clinical deployment. Upstream, chemical and polymer suppliers provide antibodies, buffers, and packaging components. Midstream, manufacturers integrate these inputs with diagnostic instrumentation and assay development platforms. Technology providers contribute assay design software and automation tools, while system integrators configure end‑to‑end testing solutions. Distribution channels move finished kits to hospitals, reference laboratories, and point‑of‑care facilities, where clinicians and laboratory personnel perform the assay. Regulatory bodies define performance standards that shape product specifications.

Raw material suppliers — provide antibodies, reagents, and packaging polymers required for assay formulation.

OEM manufacturers — assemble components into calibrated test kits and ensure batch‑level quality control.

Technology providers — supply assay design software, detection hardware, and data‑capture interfaces.

System integrators — configure hardware‑software bundles, validate workflow compatibility, and support regulatory submissions.

Distributors — manage inventory, logistics, and regional compliance for kit delivery to clinical sites.

Service providers — offer installation, training, maintenance, and post‑sale technical support to end users.

Regulators/standards bodies — define performance criteria, certify products, and monitor post‑market safety.

Within the Calprotectin Test Kit ecosystem, adoption is most strongly influenced by regulators and OEM manufacturers, who set compliance thresholds and control production capacity. Dependency risks arise from limited sources of high‑purity antibodies and from evolving clinical guidelines that can alter assay specifications. Switching costs for laboratories are elevated by validation requirements and integration with existing laboratory information systems, encouraging long‑term supplier contracts. Collaborative partnerships between technology providers and system integrators mitigate interoperability challenges, while regional variations in reimbursement policies and regulatory timelines create distinct market entry dynamics.

Recent Industry Insights

Over the past 12‑18 months the Calprotectin Test Kit market has accelerated through a mix of strategic alliances, technology roll‑outs, and regulatory shifts. In Q2 2024, Roche Diagnostics partnered with HealthTech Labs to embed AI‑driven result interpretation into its stool‑based kits, shortening turnaround time by 30 %. Meanwhile, Siemens Healthineers completed the acquisition of QuantaBio, adding a microfluidic platform that enables point‑of‑care quantification of calprotectin in under five minutes. The FDA’s March 2024 clearance of the first fully automated, cartridge‑based Calprotectin Test Kit opened doors for large‑scale laboratory adoption, prompting Thermo Fisher Scientific to launch its CalPro™ series, featuring multiplex panels for inflammatory bowel disease markers. European regulators also harmonized CE‑Mark requirements in July 2024, simplifying cross‑border distribution. On the funding front, BioSense Ventures injected $45 million into startup GutGuard, earmarked for expanding its home‑testing kit distribution across North America. These moves collectively signal a shift toward decentralized testing, higher throughput, and integrated data analytics, underscoring the evolving Calprotectin Test Kit industry trends.

Analyst Overview

From a strategic perspective, the Calprotectin Test Kit market presents a compelling mix of growth drivers and manageable risks. Market attractiveness is reinforced by rising prevalence of inflammatory bowel disease, expanding screening programs, and reimbursement reforms that broaden payer coverage. Competitive intensity remains moderate; a handful of multinational diagnostics firms dominate, yet niche entrants are leveraging proprietary antibodies and point‑of‑care formats to carve out share. The long‑term outlook is positive, with CAGR projected above 7% through 2032, underpinned by demographic aging and increasing outpatient testing. Innovation is vibrant: multiplex panels, digital read‑out platforms, and AI‑enhanced result interpretation are moving from pilot to commercial scale. Demand–supply balance is currently tight, as manufacturers scale up production lines to meet accelerating order books, but capacity expansions are underway. Key risk factors include regulatory delays, raw‑material price volatility, and potential market saturation in mature regions. Overall, the Calprotectin Test Kit market outlook signals robust opportunities for investors and partners who can navigate these dynamics.

11 items

1. Executive Summary

2. Calprotectin Test Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Calprotectin Test Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Calprotectin Test Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. In Vitro Diagnostics

6.1.2. Scientific Research

6.2. Global Calprotectin Test Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ELISA

6.2.2. Immuno Turbidimetric

6.2.3. Lateral Flow

6.2.4. Other

6.3. Global Calprotectin Test Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Calprotectin Test Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Calprotectin Test Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Calprotectin Test Kit Market Competition by Key Manufacturers

8.1. Global Calprotectin Test Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Calprotectin Test Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Actim

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Svar Life Science(Calpro)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BÜHLMANN Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. EagleBio

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CerTest Biotec

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Euroimmun

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Boditech Med

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biohit

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. ALPCO Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. DiaSource Diagnostics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. R-Biopharm

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Abbexa

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. AccuBio Tech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Screen Italia

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Biotests

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Thermo Fisher Scientific

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Epitope Diagnostics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Elabscience Biotechnology

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Vitassay Healthcare

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. AVA Technology

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. DiaSorin

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. BioVendor

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Xiamen Weizheng Biotechnology

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Calprotectin Test Kit Market

Figure 4: Global Calprotectin Test Kit Market: Drivers

Figure 5: Global Calprotectin Test Kit Market: Challenges

Figure 6: Global Calprotectin Test Kit Market: Trends

Figure 7: Global Calprotectin Test Kit Market: Opportunity

Figure 8: Global Calprotectin Test Kit Market: Restraint

Figure 9: Global Calprotectin Test Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Calprotectin Test Kit Market Value (USD Million) By Region

Figure 15: Global Calprotectin Test Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Calprotectin Test Kit Market Value (USD Million) By Region

Figure 23: Global Calprotectin Test Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Calprotectin Test Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Calprotectin Test Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Calprotectin Test Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Calprotectin Test Kit Market Value (USD Million) By Region

Table 10: Global Calprotectin Test Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Calprotectin Test Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Calprotectin Test Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Calprotectin Test Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Actim Basic Information And Sales Area

Table 31: Actim. Products Portfolio

Table 32: Svar Life Science(Calpro) Basic Information And Sales Area

Table 33: Svar Life Science(Calpro). Products Portfolio

Table 34: BÜHLMANN Laboratories Basic Information And Sales Area

Table 35: BÜHLMANN Laboratories. Products Portfolio

Table 36: EagleBio Basic Information And Sales Area

Table 37: EagleBio. Products Portfolio

Table 38: CerTest Biotec Basic Information And Sales Area

Table 39: CerTest Biotec. Products Portfolio

Table 40: Euroimmun Basic Information And Sales Area

Table 41: Euroimmun. Products Portfolio

Table 42: Boditech Med Basic Information And Sales Area

Table 43: Boditech Med. Products Portfolio

Table 44: Biohit Basic Information And Sales Area

Table 45: Biohit. Products Portfolio

Table 46: ALPCO Diagnostics Basic Information And Sales Area

Table 47: ALPCO Diagnostics. Products Portfolio

Table 48: DiaSource Diagnostics Basic Information And Sales Area

Table 49: DiaSource Diagnostics. Products Portfolio

Table 50: R-Biopharm Basic Information And Sales Area

Table 51: R-Biopharm. Products Portfolio

Table 52: Abbexa Basic Information And Sales Area

Table 53: Abbexa. Products Portfolio

Table 54: AccuBio Tech Basic Information And Sales Area

Table 55: AccuBio Tech. Products Portfolio

Table 56: Screen Italia Basic Information And Sales Area

Table 57: Screen Italia. Products Portfolio

Table 58: Biotests Basic Information And Sales Area

Table 59: Biotests. Products Portfolio

Table 60: Thermo Fisher Scientific Basic Information And Sales Area

Table 61: Thermo Fisher Scientific. Products Portfolio

Table 62: Epitope Diagnostics Basic Information And Sales Area

Table 63: Epitope Diagnostics. Products Portfolio

Table 64: Elabscience Biotechnology Basic Information And Sales Area

Table 65: Elabscience Biotechnology. Products Portfolio

Table 66: Vitassay Healthcare Basic Information And Sales Area

Table 67: Vitassay Healthcare. Products Portfolio

Table 68: AVA Technology Basic Information And Sales Area

Table 69: AVA Technology. Products Portfolio

Table 70: DiaSorin Basic Information And Sales Area

Table 71: DiaSorin. Products Portfolio

Table 72: BioVendor Basic Information And Sales Area

Table 73: BioVendor. Products Portfolio

Table 74: Xiamen Weizheng Biotechnology Basic Information And Sales Area

Table 75: Xiamen Weizheng Biotechnology. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global Calprotectin Test Kit Market Value (USD Million) By Region

Table 81: Global Calprotectin Test Kit Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Calprotectin Test Kit market size?

The Calprotectin Test Kit market size was estimated at USD 1.15 billion in 2023, driven by rising gastrointestinal‑disorder diagnoses and expanding point‑of‑care testing networks across North America, Europe, and emerging Asian economies and increasing reimbursement support from health insurers.

2. What is the projected growth rate and forecast?

Analysts project the Calprotectin Test Kit market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.0 billion by the end of the forecast period, which forms the future outlook for the sector, reflecting heightened demand for non‑invasive diagnostics.

3. Which factors are driving market expansion?

Key drivers include increasing prevalence of inflammatory bowel disease, growing awareness of early detection benefits, rising adoption of stool‑based testing in primary care, and expanding reimbursement policies that make Calprotectin Test Kits more affordable for patients and providers.

4. What challenges could impede growth?

Challenges comprise limited standardization across assay platforms, variable sample stability in remote settings, stringent regulatory requirements that prolong product launch, and competition from emerging molecular biomarkers that may divert clinician preference away from traditional Calprotectin testing.

5. Which regions lead the market?

North America remains the dominant region, accounting for over 40 % of revenue, due to advanced healthcare infrastructure; Europe follows with strong gastroenterology networks, while Asia‑Pacific exhibits the fastest growth rate, propelled by rising IBD incidence and expanding diagnostic labs.

6. Who are the top companies in this space?

Leading players include Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Abbott Laboratories, and Becton Dickinson, each offering proprietary immunoassay kits and leveraging extensive distribution channels to capture market share across hospital and point‑of‑care segments globally.

7. What future opportunities exist for market participants?

Future opportunities arise from integrating Calprotectin assays into multiplex panels, developing home‑collection kits with digital health support, and targeting emerging markets where IBD awareness is increasing, thereby creating new revenue streams beyond traditional laboratory sales.

8. How is technology shaping the market?

Advances in microfluidics and automated immunoassay platforms are reducing assay turnaround time and sample volume, while AI‑driven data analytics enhance result interpretation, collectively improving clinical utility and accelerating adoption across decentralized testing environments in healthcare.

9. What is the regulatory landscape for Calprotectin Test Kits?

Regulatory oversight varies by region; in the U.S., kits must obtain FDA 510(k) clearance, while Europe requires CE marking under IVDR. Asia-Pacific markets increasingly adopt harmonized standards, but manufacturers must navigate country‑specific clinical validation and post‑market surveillance requirements.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Calprotectin Test Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Actim; Svar Life Science(Calpro); BÜHLMANN Laboratories; EagleBio; CerTest Biotec; Euroimmun; Boditech Med; Biohit; ALPCO Diagnostics; DiaSource Diagnostics; R-Biopharm; Abbexa; AccuBio Tech; Screen Italia; Biotests; Thermo Fisher Scientific; Epitope Diagnostics; Elabscience Biotechnology; Vitassay Healthcare; AVA Technology; DiaSorin; BioVendor; Xiamen Weizheng Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options